CompletedPHASE1, PHASE2NCT03345485
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mundipharma Research Limited
- Principal Investigator
- Shivaani Kummar, MDOregon Health and Science University
- Intervention
- Tinostamustine 60mg/m2 over 30min(drug)
- Enrollment
- 71 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2023
Study locations (13)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Stanford University Medical Center, Palo Alto, California, United States
- University of Michigan, Ann Arbor, Michigan, United States
- New York University, New York, New York, United States
- Mary Crowley Cancer Research, Dallas, Texas, United States
- Juravinski Cancer Centre, Hamilton, Ontario, on, Canada
- McGill University, Montreal, Quebec, Canada
- BC Cancer-Vancouver, Vancouver, Vancouver, BC, Canada
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Istituto Europeo di Oncologia, Milan, Italy
- Erasmus MC Kanker Instituut, Rotterdam, Netherlands
- Hospital Universitario La Paz, Madrid, Fuencarral-El Pardo, Spain
- Hospital Universitari Vall d'Hebron, Barcelona, Horta-Guinardó, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03345485 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE1, PHASE2NCT06956690A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid TumorsHummingbird Bioscience